Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Hematol. 2016 Jan;9(1):79-89. doi: 10.1586/17474086.2016.1112735. Epub 2015 Nov 14.

Economic burden associated with acute myeloid leukemia treatment.

Author information

1
a Department of Internal Medicine , Yale University , New Haven , CT , USA.
2
b Celgene Corporation , Summit , NJ , USA.
3
c Pharmerit B.V ., Rotterdam , The Netherlands.
4
d Kimmel Cancer Center , Johns Hopkins , Baltimore , MD , USA.

Abstract

The economic burden associated with acute myeloid leukemia (AML) is poorly defined and understudied. The goal of this study is estimate the direct cost of illness for AML in the United States (US) and the United Kingdom (UK), by conducting a comprehensive literature review and calculating the average direct cost-of-illness per patient for the first 6 months of therapy. Patients were grouped by therapy: intensive chemotherapy alone; induction chemotherapy followed by allogeneic stem cell transplantation (alloSCT); low intensity therapy; and best supportive care. Data suggest that the pathways alloSCT, followed by intensive chemotherapy, are associated with the highest direct costs. Calculated direct costs suggest that they are higher in the US ($14,014 for BSC-only to $352,682 for alloSCT) than in the UK (£3708 [$5837] for BSC-only to £112,545 [$177,187]). AML appears to be associated with significant direct economic costs, but more studies are needed to fully assess the economic impact especially in relation to total and indirect costs.

KEYWORDS:

Acute myeloid leukemia; chemotherapy; cost of illness; economic burden; literature review; stem cell transplantation; treatment costs

PMID:
26568358
DOI:
10.1586/17474086.2016.1112735
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center